Linda S. Steelman

Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance

James A. McCubrey, Linda S. Steelman, Steven L. Abrams et al. · Advances in Enzyme Regulation · 2006 · 658 citations

Tumor Biology, Health Sciences, Pi3k/pten/akt Pathways +10

Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review).

Fumin Chang, Linda S. Steelman, John G. Shelton et al. · PubMed · 2003 · 393 citations

Apoptosis, Cell Death, Cell Cycle +19

EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review)

Patrick M. Navolanic, Linda S. Steelman, James A. McCubrey · International Journal of Oncology · 2003 · 175 citations

Epidermal Growth Factor, Breast Oncology, Downstream Signaling Pathways +17

Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors

Linda S. Steelman, Patrick M. Navolanic, Melissa L. Sokolosky et al. · Oncogene · 2008 · 171 citations · Full text

Breast Oncology, Pten Function Increases, Medicine +7

Phosphatidylinositol 3′-Kinase Activation Leads to Multidrug Resistance Protein-1 Expression and Subsequent Chemoresistance in Advanced Prostate Cancer Cells

John Tayu Lee, Linda S. Steelman, James A. McCubrey · Cancer Research · 2004 · 157 citations